Biomaterials and Bionanotechnology
Chapter 13 - Thiolated-Chitosan: A Novel Mucoadhesive Polymer for Better-Targeted Drug Delivery
Abstract
Mucoadhesion is a complex process that involves interaction (chemical and physical) between the mucin epithelial layer and polymers with mucoadhesive potential. Mucoadhesive polymers help in achieving drug delivery by adhering to mucous membranes in different parts of the body (like intestinal mucosa, oral mucosa, gastric mucosa, etc.) and provide an opportunity to attain an adequate concentration of the loaded drug at the desired site of action. In this context, thiolated chitosan is one of the most extensively utilized and favored mucoadhesive polymers, which is obtained via immobilization of thiol group on the polymeric chain of chitosan. The structural properties of chitosan uniquely allow the modification of its innate architect to sulfhydryl bearing derivatives. Upon thiol modification, the mucoadhesive, cohesive, and in situ gelling features of chitosan gets significantly improved. These modifications further augment the permeation enhancement capabilities of native chitosan and make it more suitable for vivid pharmaceutical and biomedical applications. This chapter expounds the state-of-the-art information on characteristics and methods of preparation, and a crosstalk discussion on the application of mucoadhesive thiolated chitosan as an effective delivery module is also covered in this chapter.
References (0)
Cited by (28)
Polymer mediated light responsive therapeutics delivery system to treat cancer
2024, European Polymer JournalThe concept of light therapy is not a new one in the treatment of diseases; however, the concept is relatively new in the delivery of drugs. It is particularly important to mention that the concept of light activation can be used in the specific treatment of cancer, given that heat can induce apoptotic changes in cancer cells. Our literature review discovered that most polymer-based light-responsive drug delivery systems were designed specifically to treat cancer. The present review systematically presents different types of light (ultraviolet, visible, near-infrared, etc.) and their associated responsive materials. We briefly illustrate the potential drug delivery systems that utilized light to treat cancer and utilized polymers as an integral component of the formulation. Chitosan, albumin, hyaluronic acid, polyethylene glycol, poly-L-glycolic acid, poly-lactic acid, and polycaprolactone-mediated light-sensitive systems are briefly discussed. In addition, various mechanisms by which light-activated systems work are also discussed, and a note on luminescence and bio-luminescence is also provided. At last, we critically discussed the challenges and their respective solutions point-wise. Consequently, this review can be regarded as an important step in the development of future research projects that involve the use of light as one of the components of the therapeutic effectiveness of the system.
Development of an efficient biocomposite hydrogel with enhanced mucoadhesive and antibacterial properties
2024, Results in ChemistryNoteworthy, mucoadhesion is considered an effective approach in drug delivery. Indeed, mucoadhesion donates various advantages including prolonged residence time, drug preservation, enhanced drug permeation, and developed drug accessibility. Herein, a novel gelatin based mucoadhesive hydrogel noted as gelatin/EudragitL100/Xanthan gum in combination with TiO2 and CuO metal oxides were fabricated with the aid of a facile preparation approach. In fact, the main goal of this research study is to utilize this formulation as a mucoadhesive hydrogel for the treatment of aphthous ulcers cases. To achieving and address the appropriate mucoadhesive formulation, the effect of plasticizers (PEG4000 and PG) and surfactant (SLS), kind of metal oxide and weight percent of biopolymer in formulation was studied in details. It is significant that a semi-solid formulation was obtained and examined in all experiments. Based on the results, the existence of xanthan gum, CuO and TiO2 in conjunction with Gelatin/EudragitL100 enhances the efficiency of the mucoadhesive hydrogel. It is significant that a semi-solid formulation was obtained and examined in all experiments. The as-prepared hydrogel (M7) was characterized by Fourier transform infrared (FTIR) and scanning electron microscopy (SEM). The ex vivo mucoadhesive investigation displays that the designed hydrogel possesses a convenient adhesive and biodegradation feature. The gelatin/EudragitL100/Xanthan gum/TiO2/CuO hydrogel exposed biocompatibility > 70 % for MTT assay. The in vitro swelling ratio has diminished at basic pH, owing to the smaller pore sizes, which diminishes the water absorption. Antibacterial characteristics of hydrogel (Gelatin/EudragitL100/ Xanthan gum /TiO2/CuO) on various bacteria including Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Lactobacillus plantarum and Streptococcus mutans was evaluated. The fungal surveyed species was Candida albicans ATCC 10231. The highest and lowest inhibitory effects were reported on Candida albicans and Lactobacillus plantarum, respectively. DPPH results illustrated that M7 has an appropriate radical scavenging property compared to that of reference models. All in all, the present research study addresses a significant perception regarding the utilization of mucoadhesive formulation for practical applications.
Functionalized chitosan for cancer nano drug delivery
2023, Biotechnology AdvancesChitosan is a biotechnological derivative of chitin receiving a widespread pharmaceutical and biomedical applications. It can be used to encapsulate and deliver cancer therapeutics with inherent pH-dependent solubility to confer drug targeting at tumour microenvironment and anti-cancer activity synergizing cancer cytotoxic drug actions. To further reduce the off-target and by-stander adverse effects of drugs, a high targeted drug delivery efficiency at the lowest possible drug doses is clinically required. The chitosan has been functionalized with covalent conjugates or complexes and processed into nanoparticles to encapsulate and control drug release, to avoid premature drug clearance, to deliver drugs passively and actively to cancer site at tissue, cell or subcellular levels, and to promote cancer cell uptake of nanoparticles through membrane permeabilization at higher specificity and scale. Nanomedicine developed using functionalized chitosan translates to significant preclinical improvements. Future challenges related to nanotoxicity, manufacturability, selection precision of conjugates and complexes as a function of cancer omics and their biological responses from administration site to cancer target need critical assessments.
New insights in aptamer-targeted nanoliposomes for the treatment of breast cancer
2023, Journal of Drug Delivery Science and TechnologyDespite significant advances in understanding breast cancer pathogenesis and prognosis, it remains one of the most common causes of death for women worldwide. To develop a more selective and specific treatment strategy, the drug must be efficiently targeted to breast sites with a minimum amount of drug accumulation at other sites. A possible solution to this problem has been explored extensively in recent years using aptamers (chemical antibodies). Aptamers have a higher level of specificity and biocompatibility, making them an excellent candidate for the development of cancer-targeted therapies. In addition to their extraordinary benefits, aptamers are also reported to address tumor resistance as a result of their high specificity and minimal toxicity. Thus, aptamers are expected to play an important role in the development of new therapeutics in the future. This review summarizes recent advances in aptamer-based targeted nanoliposomes for the treatment of breast cancer. A market analysis of the global aptamer market is presented as part of an effort to understand the growing use of aptamers in academic and industrial research. In addition, we discuss the challenges and future potential associated with the use of nanoliposomes as an effective anti-breast cancer therapy.
Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles
2022, International ImmunopharmacologyThe early stages of melanoma could be treated promisingly by surgical resection; however, the challenge is in advanced cases in which targeted therapy could be an option. The expression of immune checkpoints such as CTLA-4, PD-1, PD-L1, TIM-3, LAG-3, and VISTA is at adequate levels in the melanoma tumor microenvironment (TME) implying the promising outcomes of applying immune checkpoint blockades (ICBs). Since the first Food and Drug Administration (FDA) approved ICB, ipilimumab, in melanoma patients, the treatment of melanoma patients with ICBs resulted in improved survival rate and anti-tumor responses, making ICB one of the promising therapeutic approaches. However, due to high biodistribution, these drugs could non-specifically target healthy cells and empower the immune reactions out of control, which results in the incidence of immune-related adverse events. Although there are development management approaches, a new emerging platform is recently available with aid of drug delivery strategies, particularly nanoparticles (NPs). Here, we investigated the recent trials of ICBs in the context of melanoma cases while showing the challenges of this approach. Also, the application of NPs in order to locally deliver ICBs in melanoma tumor models is discussed.
Chitosan on the surface of nanoparticles for enhanced drug delivery: A comprehensive review
2022, Journal of Controlled ReleaseThe ability of chitosan (CTS) to promote mucoadhesion, trigger positive/negative surface interactions, and open tight junctions has inspired researchers to coat lipid-based and polymeric-based nanoparticles with CTS in an attempt to reach new heights in the delivery of drugs and nutraceuticals across different routes. This article discusses literature relevant to the pharmaceutical and biomedical area published in the last 10 years on nanoparticles overlaid with CTS. Herein, we addressed the technical aspects of the coating procedure by adding CTS solution to nanoparticles that have already been produced or during the production phase. Besides, we reviewed the applications of CTS coated nanoparticles as drug delivery systems in the oral and non-oral routes of administrations. Special attention was paid to the physicochemical and biological benefits of the CTS coating, such as improving physicochemical stability, enhancing cell and tissue interactions, controlled drug release, and augmentation of active substance bioavailability and efficacy. Moreover, this review projects the current standing and future prospects of the delivery system. The future calls for more investigations on therapeutic proteins, genes and vaccines as potential cargos. Extensive studies on the merits of integrating CTS with hydropolymer-synthesized nanoparticles and using longer-chain and chemically-modified variants of CTS are also warranted.